Table 3.
Complications, organ supportive therapies, and outcome in children with adenoviral pneumonia
| Complications, n (%) | Total cases, n = 85 |
|---|---|
| Acute respiratory distress syndrome | 40 (47.1) |
| Multiorgan dysfunction syndrome | 22 (25.9) |
| Shock | 21 (24.7) |
| Encephalopathy | 21 (24.7) |
| Liver dysfunction | 19 (22.3) |
| Acute kidney Injury | 17 (20) |
| Thrombocytopenia | 16 (18.9) |
| Myocardial dysfunction | 13 (15.3) |
| Coagulopathy | 5 (5.9) |
| Antimicrobials, n (%) | |
| Ceftriaxone | 35 (41.2) |
| Meropenem | 18 (21.2) |
| Vancomycin | 18 (21.2) |
| Ampicillin/Gentamicin | 14 (16.5) |
| Azithromycin | 14 (16.5) |
| Colistin | 7 (8.2) |
| Oseltamivir | 5 (5.9) |
| Cidofovir | 4 (4.7) |
| Intravenous immunoglobulin, n (%) | 7 (8.2) |
| Organ supportive therapy, n (%) | |
| Pediatric intensive care unit admission | 39 (45.9) |
| Invasive mechanical ventilation | 41 (48.2) |
| Continuous positive airway pressure | 33 (38.8) |
| High-flow nasal cannula oxygen | 8 (9.4) |
| Noninvasive ventilation | 3 (3.5) |
| Central venous catheter | 35 (41.2) |
| Blood transfusion | 25 (29.4) |
| Vasoactive drugs | 21 (24.7) |
| Renal replacement therapy | 5 (5.9) |
| Healthcare-associated infections, n (%) | 12 (14.1) |
| Ventilator-associated pneumonia | 10 (11.8) |
| Bloodstream infection | 2 (2.3) |
| Duration, median (IQR) | |
| Duration of emergency room stay (hours) | 48 (24–96) |
| Duration of pediatric intensive care unit stay (days) | 7 (4–14) |
| Duration of hospital stay (days) | 9 (5–18) |
| Outcome, n (%) | |
| Survived | 66 (77.6) |
| Deaths | 19 (22.3) |